Europe Adalimumab Market is expected to grow with the CAGR of 16.2% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/europe-adalimumab-market

Europe adalimumab market has witnessed increased strategic developments owing to favourable market scenario.

The major players dealing in Europe adalimumab market are introducing strong range of products and adopting strategic initiative such as acquisition, agreement, new product launches into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance-

• In December 2021, Alvotech announced that the company has received approval for AVT02, the company’s high concentration biosimilar to Humira (adalimumab), from the European Commission (EC) on Nov. 15. This has helped the company to increase its global presence through this approval.

AbbVie Inc. is the dominating player in the Europe adalimumab market. The other key players existing in the market include Sandoz International GmbH, Amgen Inc., Mylan N.V. (A subsidiary of Viatris), Biogen, Celltrion Healthcare Co., Ltd., Fresenius Kabi SwissBioSim GmbH, Alvotech, Biocad, Coherus BioSciences, Shanghai Henlius Biotech, Inc., Synermore Biologics, Prestige BioPharma Ltd., and Janssen Global Services, LLC among others.

AbbVie Inc.

AbbVie Inc. has its headquarters in North Chicago, Illinois, United States. The company was launched in 2013. AbbVie Inc. is focused on discovering and delivering transformational medicines and products in several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, and women’s health, as well as through our Allergan Aesthetics portfolio.

The company is engaged in the continuous development of Adalimumab.

For instance,

• In February 2021, AbbVie Inc., announced that U.S. Food and Drug Administration (FDA) approved HUMIRA (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients 5 years of age and older. This has helped the company to increase its global presence and increase the revenue from the product.

The company has a wide presence across North America, Europe, Asia-Pacific, South America, and Middle East and Africa. The company also has various subsidiary companies such as Allergan USA, Inc. (U.S.), Allergan Sales, LLC (U.S.), Forest Laboratories Holdings Limited (U.S.)       among others.

Amgen Inc.

Amgen Inc. has its headquarters in Thousand Oaks, California, United States, and was established in 1980. The company focuses on six therapeutic areas: cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation. Company’s medicines typically address diseases for which there are limited treatment options, or they are medicines that provide a viable option to what is otherwise available.

The company is engaged in continuous development.

For instance,

• In October 2021, Amgen Inc. announced that the company has completed its acquisition of Teneobio, Inc. This has helped the company to expand its product portfolio and research in the new medicine formation.

The company has a wide presence across North America, Europe, Asia-Pacific, and Middle East and Africa. The company also has various subsidiary companies such as Amgen (Europe) GmbH (Switzerland), Amgen Canada Inc. (Canada), Amgen Fremont Inc. (Delaware), Amgen Global Finance B.V.(Netherlands), and Amgen GmbH Germany (Germany) among others.

Biogen

Biogen has its headquarters in Cambridge, Massachusetts, United States, and was founded in 1978. Biogen has led innovative scientific research with the goal over the last decade to defeat devastating neurological diseases.

The company is engaged in the continuous development of Adalimumab.

For instance,

• In October 2018, Biogen launched IMRALDI, a biosimilar adalimumab in European region. This product launched helped the European citizens to get relief from several types of inflammatory conditions involving arthritis, adolescent hidradenitis suppurativa, Crohn’s disease, pediatric plaque psoriasis among others. This product launched enhanced the company’s product portfolio and allowed it to earn more revenue in the market.

The company has a wide presence across North America, Europe, Asia-Pacific, and Middle East and Africa.